186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation.
In connection with our work on the development of 186Re-tetra-phosphonates with optimum properties for use in bone pain palliation, a novel cyclic tetraphosphonate derivative, has been synthesized, complexed with 186Re and evaluated with promising results. The ligand, which consists of a cyclic array of tetra-aminomethylphosphonate groups, was synthesized using orthophosphorus acid, 1,4,8,11-tetraazacyclotetradecane and formaldehyde. The labeling conditions with 186Re have been standardized under varying reaction conditions to give maximum yield. In a reaction volume of 1 mL, maximum complexation yield of 98% was observed at pH 2 using 0.1 mg Re (37-370 MBq) for a ligand concentration at 9 x 10(-2) M/L, under heating at 100 degrees C for 30 min with 2 mg of stannous chloride. The complex was found to be stable for 6 days with RC purity remaining approximately 97%. The complex was characterized by paper chromatography in saline and acetone, wherein the R(f) exhibited were 0.9 and 0, respectively. Biodistribution studies of the complex were performed in male Wistar rats. Activity in femur which was observed to be 1.8%/g (equivalent to about 23% of the injected activity in skeleton) at 3 h post injection remained almost constant up to 48 h. Minimum activity was observed in blood and other soft tissues. The complex showed major renal clearance. Scintigraphic images in rabbits after injecting 70-100 MBq of 186Re-CTMP and using a dual head gamma camera were observed to be superior to 186Re-HEDP, prepared by a procedure standardized by us. Insignificant activity was observed in other vital organs. The results suggest the suitability of the complex for further evaluation in higher animals for bone pain palliation.
Kothari
K
K
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, 400 085, Mumbai, India.
Samuel
G
G
Banerjee
S
S
Unni
P R
PR
Sarma
H D
HD
Chaudhari
P R
PR
Unnikrishnan
T P
TP
Pillai
M R
MR
D000700:Analgesics / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary; D012968:Etidronic Acid / Q000493:pharmacokinetics*; D006573:Heterocyclic Compounds, 1-Ring / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000627:therapeutic use; D007275:Injections, Intravenous; D008297:Male; D009942:Organometallic Compounds; D063065:Organophosphonates / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012211:Rhenium / Q000493:pharmacokinetics*; D014018:Tissue Distribution
C440011:1,4,8,11-tetraazacyclotetradecyl-1,4,8,11-tetramethylenephosphonic acid; D000700:Analgesics; D006573:Heterocyclic Compounds, 1-Ring; D009942:Organometallic Compounds; D063065:Organophosphonates; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid